Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) FCF Margin (2019 - 2025)

Keros Therapeutics (KROS) has disclosed FCF Margin for 6 consecutive years, with 7588.95% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 1670253.0% year-over-year to 7588.95%, compared with a TTM value of 43.45% through Dec 2025, down 19610113.0%, and an annual FY2025 reading of 43.45%, changed N/A over the prior year.
  • FCF Margin was 7588.95% for Q4 2025 at Keros Therapeutics, down from 32.19% in the prior quarter.
  • Across five years, FCF Margin topped out at 1050500.0% in Q1 2021 and bottomed at 431650.0% in Q3 2023.
  • Average FCF Margin over 5 years is 33531.33%, with a median of 138.6% recorded in 2021.
  • The sharpest move saw FCF Margin crashed -105050874bps in 2022, then surged 42368969bps in 2024.
  • Year by year, FCF Margin stood at 110.19% in 2021, then soared by 213bps to 124.82% in 2022, then plummeted by -13622bps to 16877.62% in 2023, then surged by 154bps to 9113.58% in 2024, then crashed by -183bps to 7588.95% in 2025.
  • Business Quant data shows FCF Margin for KROS at 7588.95% in Q4 2025, 32.19% in Q3 2025, and 167.01% in Q2 2025.